Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital-at-Home. Executive Order 1042, Requirements for COVID-19 VAccination of Federal Contractors and DOL OSHA COVID-19 VAccination Rules. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 4502 - FY2022 Consolidated Appropriations, H.R. 5376 the Build Back Better Act
Corporate and international tax and tariff policy; Sec. S965 and GILTI
Veterans and Military Health, inclduing funding opportunities; VA procurement and payment reforms; prompt pay, veterans choice program issues. Buy America policy.
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 5376 the Build Back Better Act.
Appropriations, government funding and program opportunities. Labor-HHS FY 22 Appropriations.
Issues regarding trade and supply chains; Buy America policy
Duration: January 1, 2009
to
December 31, 2021
General Issues: Health Issues , Taxation/Internal Revenue Code , Veterans , Medicare/Medicaid , Budget/Appropriations , Trade (Domestic & Foreign)
Spending: about $7,175,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Homeland Security - Dept of (DHS), Treasury - Dept of, Vice President of the U.S., Office of the Vice President of the United States, Occupational Safety & Health Administration (OSHA), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
Hill-Rom Holdings in-house lobbying effort was terminated on Jan. 19, 2022
Original Filing: 301326942.xml
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital-at-Home. Executive Order 1042, Requirements for COVID-19 VAccination of Federal Contractors and DOL OSHA COVID-19 VAccination Rules. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 4502 - FY2022 Consolidated Appropriations, H.R. 5376 the Build Back Better Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) White House Office
Lobbying Issues
Corporate and international tax and tariff policy; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Veterans and Military Health, inclduing funding opportunities; VA procurement and payment reforms; prompt pay, veterans choice program issues. Buy America policy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 5376 the Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Appropriations, government funding and program opportunities. Labor-HHS FY 22 Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding trade and supply chains; Buy America policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 19, 2021.
Original Filing: 301305231.xml
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital-at-Home. OSHA standards and rules related to vaccinations. S. 748, the Medciare Sequester Relief Act, H.R. 315, the Medciare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 4502 - FY2022 Consolidated Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Corporate and international tax and tariff policy; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Veterans and Military Health, inclduing funding opportunities; VA procurement and payment reforms; prompt pay, veterans choice program issues. Buy America policy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Appropriations, government funding and program opportunities. Labor-HHS FY 22 Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding trade and supply chains. Buy America policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301281807.xml
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital-at-Home. S. 748, the Medciare Sequester Relief Act, H.R. 315, the Medciare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Corporate and international tax and tariff policy; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Veterans and Military Health, inclduing funding opportunities; VA procurement and payment reforms; prompt pay, veterans choice program issues. Buy America policy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Appropriations, government funding and program opportunities. labor-HHS FY 22 Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding trade and supply chains. Buy America policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265621.xml
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. S. 748, the Medciare Sequester Relief Act, H.R. 315, the Medciare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Corporate and international tax and tariff policy; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Veterans and Military Health, inclduing funding opportunities; VA procurement and payment reforms; prompt pay, veterans choice program issues. Buy America policy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding COVID short and long term chalenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation, supply chain issues; Medicare and Medicaid coverage and reimbursement; artifical intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, mobility standards, safe patient handling, and health infrastructure funding and initiatives. S. 748, the Medciare Sequester Relief Act, H.R. 315, the Medciare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Appropriations, government funding and program opportunities
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding trade and supply chains. Buy America policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301234109.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748);and the Heroes Act (H.R.6800) Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Homeland Security - Dept of (DHS)
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748; Sec. S965 and GILTI; the HEROES Act (H.R. 6800)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6074),the CARES Act (S. 3548/H.R. 748); and the HEROES Act (H.R. 6800); Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2020
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301218102.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6704), the CARES Act (S. 3548/H.R. 748);and the Heroes Act (H.R.6800) Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254),
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Homeland Security - Dept of (DHS)
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748; Sec. S965 and GILTI; the HEROES Act (H.R. 6800)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6704),the CARES Act (S. 3548/H.R. 748); and the HEROES Act (H.R. 6800); Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2020
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301191751.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6704) and the CARES Act (S. 3548/H.R. 748); Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Health & Human Services - Dept of (HHS) Homeland Security - Dept of (DHS)
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6704) and the CARES Act (S. 3548/H.R. 748); Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2020
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 19, 2020.
Original Filing: 301172768.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (H.R. 6704) and the CARES Act (S. 3548/H.R. 748); Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA Reform; Sepsis funding and education; Further Consolidated Appropriations Act of 2020 (H.R. 1865), Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Vice President of the U.S.
Type of Issue
Health Issues Medicare/Medicaid
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748; Sec. S965 and GILTI
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2019
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 17, 2020.
Original Filing: 301110452.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform; Labor Health and Human Services, Education, Defense, State, Foreign Operations and Energy and Water Development Appropriations Act, 2020 (H.R. 1865); Sepsis funding and education; Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Lobbying Issues
Medical device excise tax repeal (H.R. 2207, S. 692); taxation of medical technology; Further Consolidated Appropriations Act of 2020 (H.R.1865)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform, Extension of Continuing Appropriations Act of 2020. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 1865); Sepsis funding and education; and Diabetic Vision Loss and Blindness Prevention Act (H.R. 5254)
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2019
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 15, 2019.
Original Filing: 301065993.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform; Labor Health and Human Services, Education, Defense, State, Foreign Operations and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical device excise tax repeal (H.R. 2207, S. 692); taxation of medical technology
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform, Extension of Continuing Appropriations Act of 2018. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740); Sepsis funding and education
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2019
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 12, 2019.
Original Filing: 301045268.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform; Labor Health and Human Services, Education, Defense, State, Foreign Operations and Energy and Water Development Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical device excise tax repeal (H.R. 2207, S. 692); taxation of medical technology
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform, Extension of Continuing Appropriations Act of 2018. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2019
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 15, 2019.
Original Filing: 301025536.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Medical device excise tax repeal (H.R. 2207, S. 692); taxation of medical technology
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP Reauthorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA Reform, Extension of Continuing Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2018
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 18, 2019.
Original Filing: 301009041.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of Continuing Appropriations Act of 2018; H.R. 6639 Diabetic Retinopathy Vision Loss and Blindness Prevention Act, Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical Device Tax Repeal (HR 184); corporate tax reform; taxation of medical technology
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research. Implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); Diabetic RetinopathyVision Loss and Blindness Prevention Act of 2018; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of continuing Appropriations; Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2018
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 18, 2018.
Original Filing: 300988698.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of Continuing Appropriations Act of 2018; H.R. 6639 Diabetic Retinopathy Vision Loss and Blindness Prevention Act, Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical Device Tax Repeal (HR 184); corporate tax reform; taxation of medical technology
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research. Implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of continuing Appropriations; Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2018
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300972242.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of continuing Appropriations; Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Medical Device Tax Repeal (HR 184); corporate tax reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research. Implementation of Patient Protection and Affordable care Act (HR 3590/PL 111-148); Health Care and Education Reconciliation Act (HR 4872/PL 111-152); the Protect Medical Innovation Act (HR 1041/S108); the implementation of the medicare Access and CHIP reauthorization Act (HR 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling,FDA reform;Extension of continuing Appropriations; Medical Device Tax Repeal (HR 184)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2018
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 7, 2018.
Original Filing: 300942868.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152), the Protect Medical Innovation Act (H.R. 1041/S.108); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Vice President of the U.S.
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
4th Quarter, 2017
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300928355.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152), the Protect Medical Innovation Act (H.R. 1041/S.108); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Vice President of the U.S. White House Office
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Office of the Vice President of the United States
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 13, 2017.
Original Filing: 300903834.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Vice President of the U.S. White House Office
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Office of the Vice President of the United States
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 18, 2017.
Original Filing: 300887750.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Vice President of the U.S. White House Office
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices e.g. (Patient Protection and Affordable Care Act (H.R. 3590/P.L. 11-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 11-152), the Protect Medical Innovation Act (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2). Telemedicine and connected care; remote patient monitoring including: Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S. 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642). Safe Patient Handling, FDA Reform, Technology research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Office of the Vice President of the United States
1st Quarter, 2017
Hill-Rom Holdings amended a lobbying report for in-house lobbying in Q12017 on April 19, 2017
Original Filing: 300869621.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
VA Procurement and payment reforms
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 14, 2017.
Original Filing: 300865535.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2016
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 18, 2017.
Original Filing: 300849026.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2016
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 13, 2016.
Original Filing: 300827445.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2016
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 19, 2016.
Original Filing: 300814893.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corproate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2016
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 15, 2016.
Original Filing: 300791879.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medial Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2015
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 11, 2016.
Original Filing: 300770277.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit,Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2015
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 14, 2015.
Original Filing: 300752948.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit,Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2015
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 9, 2015.
Original Filing: 300732521.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Trade Promotion Authority/TPP
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 2, 2015.
Original Filing: 300712333.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 13, 2015.
Original Filing: 300694805.xml
Lobbying Issues
Health Care Reform Implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 13, 2014.
Original Filing: 300675439.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 2, 2014.
Original Filing: 300653418.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Competitive Bidding of Durable Medical Equipment, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 9, 2014.
Original Filing: 300633548.xml
Lobbying Issues
Health Care Reform implementation & Taxation of Medical Technology Devices, Competitive Bidding of Durable Medical Equipment, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 12, 2014.
Original Filing: 300612784.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices, Competitive Bidding of Durable Medical Equipment, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 13, 2013.
Original Filing: 300593166.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices, Competitive Bidding of Durable Medical Equipment, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 17, 2013.
Original Filing: 300573683.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices, Competitive Bidding of Durable Medical Equipment, Safe Patient Handling, FDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices, R&D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 15, 2013.
Original Filing: 300549730.xml
Lobbying Issues
Taxation of Medical Technology Devices, R& D Tax Credit, Corporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 15, 2013.
Original Filing: 300528883.xml
Lobbying Issues
Taxation of Medical Technology Devices
R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 18, 2012.
Original Filing: 300511347.xml
Lobbying Issues
Taxation of Medical Technology Devices
R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives U.S. Senate Occupational Safety & Health Administration (OSHA)
2nd Quarter, 2012
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 4, 2012.
Original Filing: 300480750.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Taxation of Medical Technology Devices
R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 17, 2012.
Original Filing: 300461948.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Taxation of Medical Technology Devices
R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 2, 2012.
Original Filing: 300434037.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Research & Development Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 12, 2011.
Original Filing: 300412466.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Research & Development Tax CreditCorporate Tax Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
Hill-Rom Holdings amended a lobbying report for in-house lobbying in Q32011 on Oct. 12, 2011
Original Filing: 300412616.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Research & Development Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 11, 2011.
Original Filing: 300387681.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Research & Development Tax CreditFDA Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 14, 2011.
Original Filing: 300363488.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Handling
Research & Development Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300347651.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Lifting
Research & Development Tax CreditEmployee Free Choice Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 19, 2010.
Original Filing: 300319886.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Competitive Bidding of Durable Medical Equipment
Safe Patient Lifting
Research & Development Tax Credit
Employee Free Choice Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 14, 2010.
Original Filing: 300285808.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Title Transfer for Air Fluidize Therapy
Research & Development Tax Credit
Employee Free Choice ActCompetitive Bidding of Durable Medical Equipment
Safe Patient Lifting
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 14, 2010.
Original Filing: 300257653.xml
Lobbying Issues
Health Care Reform & Taxation of Medical Technology Devices
Title Transfer for Air Fluidize Therapy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, Hill-Rom Holdings had in-house lobbyists. The report was filed on Jan. 11, 2010.
Original Filing: 300228871.xml
Lobbying Issues
Health Care Reform & Taxation of Medical of Medical Technology Devices
Title Transfer for Air Fluidize Therapy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, Hill-Rom Holdings had in-house lobbyists. The report was filed on Oct. 15, 2009.
Original Filing: 300205011.xml
Lobbying Issues
Health Care Reform and Taxation of Medical Technology Devices
Title Transfer for Air Fluidize Therapy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, Hill-Rom Holdings had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300183479.xml
Lobbying Issues
Title transfer for air fluidize therapy
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2009
In Q1, Hill-Rom Holdings had in-house lobbyists. The report was filed on April 17, 2009.
Original Filing: 300153297.xml
Lobbying Issues
Title transfer of air fluidized therapy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate